|Scientific Subdivisions | The Journal of Molecular Diagnostics | Contact AMP | Sign In | Join / Renew | Go To CHAMP|
AMP 2013 Annual Meeting
November 14-16, 2013
Phoenix Convention Center
Corporate Workshop Day
November 13, 2013
Visit Meeting Page
October 2013: Comments detail concerns about the Palmetto Molecular Diagnostics (MolDX) Services Program and Medicare coverage as well as their impact on Gap Fill Pricing for Molecular Pathology Procedures.
September 2013: In the past four weeks, AMP has submitted comments to the CMS and Palmetto on issues related to reimbursement and patient care. AMP will continue to advocate on behalf of its members and the field of molecular diagnostics.
Join your colleagues, November 14-16, 2013 in Phoenix for the AMP Annual Meeting. Online registration is available through early November. Come out a day early for Corporate Workshop Day on Nov. 13!
View the most recent edition of AMPlifications including updates on AMP's education, advocacy, and patient care-related initiatives.
September 2013: “While we hold all AMP members and others in the field in the highest esteem, the winners of these prestigious awards have truly excelled in their work, their dedication to AMP and the advancement of molecular pathology," said Jennifer L. Hunt, MD, MEd, AMP President.
June 2013: AMP has joined the Federation of American Societies for Experimental Biology (FASEB). "Being a member of FASEB will enable AMP's voice to be even stronger," said Jennifer L. Hunt, MD, MEd, AMP President.
AMP is very pleased with the Supreme Court’s decision in the case. The Court’s decision that human genes are not patentable is a great step forward for the field of molecular pathology, for genomic science, and most important for our patients. We look forward to exciting future advancements in diagnostic testing and therapeutics that will accrue to the benefit of our patients and our field.
Link to decision from Supreme Court of the United States: http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf
May 2013: A coalition representing over 120,000 medical and laboratory professionals and institutions that perform the vast majority of clinical molecular pathology testing in the United States released a joint statement regarding new Medicare prices for those tests.
The guideline was developed to establish standards for testing for EGFR and ALK, helping to guide targeted therapies. Pathologists are encouraged to implement the new guideline at their institutions and into their practices to help improve the effectiveness of lung cancer treatment. More information...
View the webcast (wmv file)